Investigational drug · Phase 2
CPT-11
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastrointestinal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
347
Any phase or sponsor naming "CPT-11"
First trial start
2025
Mar 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CPT-11", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastrointestinal Cancer
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CPT-11" as an intervention, largest first.
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00079274 · 3,397 participants · Start Feb 2004 · Primary completion Nov 2012
Drug: irinotecan hydrochloride; oxaliplatin and 4 more · For: Adenocarcinoma of the Colon; Stage III Colon Cancer
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 894 sites in all
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00265850 · 2,334 participants · Start Nov 2005 · Primary completion Feb 2015
Drug: bevacizumab; cetuximab and 2 more · For: Colorectal Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Fort Smith, Arkansas · 683 sites in all
- Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerPivotal-lookingStatus unknown
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
NCT00091312 · 1,976 participants (planned) · Start Jun 2004
Drug: FOLFIRI regimen; fluorouracil and 2 more · For: Colorectal Cancer
Sites: Cairo, Egypt; Boulogne-Billancourt, France; Dijon, France · 9 sites in all
- Combination Chemotherapy in Treating Patients With Advanced Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00003594 · 1,691 participants · Start Oct 1998 · Primary completion Oct 2004
Drug: irinotecan; fluorouracil and 2 more · For: Colorectal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 466 sites in all
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT01039506 · 1,376 participants · Start Oct 15, 2009 · Primary completion Apr 28, 2016
Drug: CPT-11 based regimens · For: Metastatic Colorectal Cancer
Sites: Tokorozawa-shi, Japan
- Combination Chemotherapy in Treating Patients With Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00003835 · 1,260 participants (planned) · Start May 1999 · Primary completion Aug 2007
Drug: leucovorin calcium; fluorouracil and 1 more · For: Adenocarcinoma of the Colon; Stage III Colon Cancer
Sites: Chicago, Illinois
- Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the StomachPivotal-lookingCompleted
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT01640782 · 1,100 participants · Start Feb 2005 · Primary completion Jan 2013
Drug: Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin; Leucovorin, 5-Fluorouracil · For: Adenocarcinoma of the Stomach; Adenocarcinoma of the Gastroesophageal Junction
Sites: Fabriano, Italy; Senigallia, Italy; Torrette Di Ancona, Italy · 101 sites in all
- Irinotecan Plus Thalidomide in Second Line Advanced Gastric CancerPivotal-lookingStatus unknown
Wang JufengAcademic, hospital or other
NCT02401971 · 900 participants (planned) · Start Aug 2014 · Primary completion Aug 2016
Drug: Thalidomide; CPT-11 · For: Gastric Cancer
Sites: Zhengzhou, China
- A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric CancerPivotal-lookingCompleted
Japan Clinical Oncology GroupAcademic, hospital or other
NCT00142350 · 690 participants · Start Nov 2000
Drug: continuous infusion of 5-fluorouracil; combination of irinotecan and cisplatin and 1 more · For: Gastric Cancer
Sites: Nagoya,Chikusa-ku,Kanokoden,1-1, Japan; Nagoya,Naka-ku,Sannomaru,4-1-1, Japan; Okazaki,Kake-machi,Kuriyado,18, Japan · 34 sites in all
- A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRCPivotal-lookingCompleted
Epidemiological and Clinical Research Information NetworkAcademic, hospital or other
NCT01996306 · 650 participants · Start Dec 2, 2013 · Primary completion Nov 20, 2017
Drug: Bevacizumab; CPT-11 (Irinotecan) and 6 more · For: Colorectal Neoplasms; Neoplasm Metastasis; Intestinal Neoplasms and 2 more
Sites: Kyoto, Japan
Newest research
PubMed records naming it or its code names, newest first.
- In depth study on the mechanism of Xiao-Chai-Hu-Tang in ameliorating irinotecan-induced intestinal toxicity and enhancing antitumor immunity via intestinal microbiota and fecal metabolomics.
Zhang Y, Cao X, Hou Z, et al. · J Pharm Biomed Anal 2026
- Anticancer drug interactions with BP@Au nanomatrix in laser desorption/ionization mass spectrometry.
Umar M, Cao A, Mandal G, et al. · Colloids Surf B Biointerfaces 2026
- Title: Topoisomerase I Inhibition Serves as a Tumor Vaccine by Inducing the ERVs-dsRNA-Interferon Pathway.
Lin Y, Ren Y, Jing D, et al. · Pharmacol Res 2026
- Hybrid Liposome-U87MG Membrane Nanovesicles Enhance Brain Delivery and Therapeutic Efficacy of Irinotecan in Orthotopic Glioma.
Li S, Sun Y, Liu Y, et al. · Int J Nanomedicine 2026
- Angelica sinensis polysaccharide ameliorates chemotherapy-induced intestinal mucositis by regulating gut microbiota-mediated innate immunity and short-chain fatty acid production in Drosophila and mice.
Wang Y, Zhang Y, Yue S, et al. · Int J Biol Macromol 2026
- Longitudinal Gut Microbiota Changes in Mouse Models of Chronic Colitis, Colitis-Associated Cancer, and Chemotherapy-Induced Diarrhea.
Hu J, Yang A, Li X, et al. · J Gastroenterol Hepatol 2026
Also in development for Gastrointestinal Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- RMC-9805Phase 23 trials
Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC
- DB-1324Phase 21 trial
DualityBio Inc. · Gastrointestinal Cancer
- DR30206Phase 21 trial
Zhejiang Doer Biologics Co., Ltd. · Gastrointestinal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.